Table 2 |
||||||||
| The methodological quality of included studies based on the Cochrane handbook | ||||||||
| A | B | C | D | E | F | G | H | |
| WU2005[31] | ? | - | - | - | - | + | + | - |
| Yu 2005[32] | + | - | - | - | - | + | ? | + |
| Tan 2006[35] | ? | - | - | - | - | + | - | - |
| Yu 2006[36] | ? | - | - | - | - | - | + | - |
| Wu 2008[42] | ? | - | + | - | - | + | ? | - |
| She2009[37] | + | - | - | - | - | + | ? | + |
| Yuan2009[38] | + | - | - | - | - | + | ? | + |
| Luo 2009[34] | ? | - | - | - | - | + | ? | - |
| Zou 2011[40] | ? | - | - | - | - | + | - | - |
| Cong 2011[41] | ? | - | - | - | - | + | + | - |
| Feng 2011[39] | ? | - | - | - | - | + | ? | - |
| Liu 2012[33] | ? | - | - | - | - | + | - | - |
A: Adequate sequence generation; B: Concealment of allocation; C: Blinding (patient); D: Blinding(investigator); E: Blinding(assessor); F: Incomplete outcome data addressed (ITT analysis); G:Free of selective reporting; H: other potential thereat to validity. +: Yes, -: No, ?: Unclear.
Xie et al. BMC Complementary and Alternative Medicine 2013 13:18 doi:10.1186/1472-6882-13-18
